Viridian Therapeutics, Inc. - Common Stock (VRDN)

In a major victory for its rare disease portfolio, Amgen (NASDAQ: AMGN) announced positive topline results on April 6, 2026, from its pivotal Phase 3 clinical trial evaluating a subcutaneous (SC) formulation of TEPEZZA (teprotumumab-trbw). The study, which utilized a convenient on-body injector, demonstrated efficacy that mirrors the high bar

The biotechnology sector witnessed a seismic shift this week as Roivant Sciences (Nasdaq: ROIV) and its subsidiary Immunovant (Nasdaq: IMVT) reported a series of clinical and regulatory updates that have fundamentally reshaped the competitive landscape for autoimmune treatments. As of April 2, 2026, Roivant has reached a multi-year valuation peak,

This clinical-stage biotech develops antibody therapies for thyroid eye disease, advancing multiple candidates through its R&D pipeline.

Spyre Therapeutics focuses on antibody therapies for inflammatory bowel disease, advancing a pipeline aimed at gastrointestinal health.

Clinical-stage biotech Dianthus Therapeutics develops antibody therapies for severe autoimmune and neuromuscular conditions.

This Boston-based biotech develops therapies for neurological disorders, with a pipeline targeting depression, tremor, and rare epilepsies.

This ophthalmic biopharma firm develops sustained drug delivery therapies for eye diseases, targeting both U.S. and global markets.

This clinical-stage biotech develops inhaled therapies for rare respiratory diseases, with its lead candidate in Phase III trials.

Viridian Therapeutics develops monoclonal antibody therapies targeting rare diseases, with a focus on thyroid eye disease treatments.

Is Cidara Therapeutics a Buy After HighVista Strategies Initiated a Position in the Stock?

Viridian Therapeutics (VRDN) exemplifies the Minervini SEPA strategy, combining a strong technical uptrend with explosive fundamental sales and earnings growth momentum.

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.

The company's drug led to an improvement in diplopia, or double vision, an area where Amgen's Tepezza hasn't worked.